AILERON THERAPEUTICS
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell.
AILERON THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2005-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.aileronrx.com
Total Employee:
11+
Status:
Active
Contact:
+1 617 995 0900
Email Addresses:
[email protected]
Total Funding:
256.21 M USD
Technology used in webpage:
HSTS Amazon JQuery CDN Mobile Optimized Amazon Frankfurt Region Pexels Unsplash Drupal Adobe Dynamic Tag Management Drupal 10
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
CAMP4 Therapeutics
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-11-01 | Lung Therapeutics | Lung Therapeutics acquired by Aileron Therapeutics | N/A |
Investors List
Nantahala Capital Management
Nantahala Capital Management investment in Post-IPO Equity - Aileron Therapeutics
Bios Partners
Bios Partners investment in Post-IPO Equity - Aileron Therapeutics
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Secondary - Aileron Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Secondary - Aileron Therapeutics
Grand Oaks Capital
Grand Oaks Capital investment in Post-IPO Secondary - Aileron Therapeutics
Satter Investment Management
Satter Investment Management investment in Post-IPO Secondary - Aileron Therapeutics
Maven Investment Partners US
Maven Investment Partners US investment in Post-IPO Secondary - Aileron Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Secondary - Aileron Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series E - Aileron Therapeutics
Excel Venture Management
Excel Venture Management investment in Series E - Aileron Therapeutics
Key Employee Changes
Official Site Inspections
http://www.aileronrx.com Semrush global rank: 4.63 M Semrush visits lastest month: 2.07 K
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aileron Therapeutics"
Aileron Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 617 995 0900 Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides.See details»
aileronrx.com - Whois.com
Jan 5, 2007 Whois Lookup for aileronrx.com. Login Sign up My Account Logout; Domains. ... Not Available From Registry Registrant Name: Registration Private Registrant Organization: …See details»
Aileron Expands Management Team with Appointment of …
Apr 21, 2022 Visit us at aileronrx.com to learn more. Forward-Looking Statements Statements in this press release about Aileron’s future expectations, plans and prospects, as well as any …See details»
Aileron Therapeutics - LinkedIn
Aileron Therapeutics | 7,452 followers on LinkedIn. Developing novel medicines to provide better treatment options for patients with life-threatening pulmonary conditions. | Following the ...See details»
Working At Aileron: Company Overview and Culture - Zippia
Aileron's DOC System is a proven approach to running a thriving business that has empowered thousands of leaders to transform their businesses Founded in 1996, Aileron is an established …See details»
Aileron Therapeutics Company Profile 2024: Stock
Aileron Therapeutics General Information Description. Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases.See details»
Aileron Therapeutics - Overview, News & Similar companies
Oct 30, 2023 Aileron Therapeutics contact info: Phone number: (617) 995-0900 Website: www.aileronrx.com What does Aileron Therapeutics do? Aileron is a chemoprotection …See details»
Aileron Therapeutics - Craft
Oct 29, 2024 Aileron Therapeutics has 4 employees across 2 locations. See insights on Aileron Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Aileron Therapeutics Announces CEO Transition - Aileron
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in …See details»
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Nov 1, 2023 For more information on the acquisition, please visit the investor section of Aileron's website at investors.aileronrx.com. About Aileron Therapeutics Following the acquisition of …See details»
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Oct 31, 2023 Management and Organization. ... An updated corporate presentation can be found at www.aileronrx.com in the Events & Presentations section. Conference Call Details . …See details»
Aileron Therapeutics Provides Business Update and Outlines 2021 ...
Dec 21, 2020 617-995-0900 [email protected] [email protected]. Hans C. Vitzthum LifeSci Advisors, LLC. 617-430-7578 [email protected] _____ 1 American …See details»
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 ...
Apr 15, 2024 Aileron Therapeutics, Inc. Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, …See details»
Aileron Therapeutics (ALRN) Announces Acquisition of Lung …
Oct 31, 2023 An updated corporate presentation can be found at www.aileronrx.com in the Events & Presentations section. Conference Call Details Aileron will host a conference call on …See details»
Aileron Therapeutics Announces Completion of $35.9 Million …
Jan 11, 2021 \-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering \--– Aileron plans to use …See details»
Aileron Therapeutics Announces $35.9 Million Registered Direct …
Jan 6, 2021 617-430-7578 [email protected] Contact: Liz Melone 617-256-6622 [email protected]. WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- …See details»
Aileron Therapeutics Provides Business Update and Outlines 2022 ...
Jan 5, 2022 Visit us at aileronrx.com to learn more. Forward-Looking Statements Statements in this press release about Aileron’s future expectations, plans and prospects, as well as any …See details»
Aileron Therapeutics Presents Initial Findings from Ongoing
Aug 27, 2021 Investor Contacts: Media Contact: Richard Wanstall, SVP Chief Financial Officer: Liz Melone: Aileron Therapeutics: 617-256-6622: 617-995-0900: [email protected]See details»
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual …
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy …See details»